Document is current
Any future updates will be listed below
-
Authors
Hassanein, Mohamed https://orcid.org/0000-0001-6598-6972
Alawadi, Fatheya
AlKadhim, Ibrahim
Aly, Hazem
Bajawi, Dalila
Cinar, Tarhan
Dhanwal, Dinesh
Jabbar, Abdul
Khader, Said
Khudadah, Khaled
Muzaffar, Talal
Ngome, Mary
Nafach, Jalal
Shaghouli, Amna
,
Alsaeed, Abdulghani
Haroon, Abuljaboor
Al Jammah, Anwar
Bashier, Alaaeldin
Atta, Aref
Nassar, Ayham
Mahmood, Dhafir
Rashid, Fauzia
Steitieh, Habib
Bajwa, Hammad
Al Quraini, Hussain
Aldossari, Khaled
Jallo, Mahir
Hatahet, Mohamed
Alrandi, Muneera
Zied, Nedal Abu
Nader, Rita
El Baba, Sarah
Ajaz, Yasmeen
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05716724 at ClinicalTrials.govDocuments that mention this clinical trial
O-SEMA-FAST: A Prospective, Non-interventional Study Investigating Oral Semaglutide Use in Adults with Type 2 Diabetes Mellitus During Ramadan
https://doi.org/10.1007/s13300-025-01702-1
-
Funding
Funding for this research was provided by:
Novo Nordisk
- License Information
-
More Information
Article History
Received: 16 December 2024
Accepted: 29 January 2025
First Online: 28 February 2025
Declarations
:
: Mohamed Hassanein has received honorarium from Novo Nordisk, Eli Lilly, Sanofi, Novartis and MSD; has received Lecture/Other Fees from Novo Nordisk, Eli Lilly, Sanofi, Novartis and MSD and he is a principal investigator. Fatheya Al Awadi has nothing to disclose. Ibrahim AlKadim has received honorarium from Novo Nordisk and Eli Lilly; has received Lecture/Other Fees from Novo Nordisk, AstraZeneca, Sanofi, Eli Lilly, Boehringer Ingelheim, SPIMACO and he has shares in Novo Nordisk and Eli Lilly. Hazem Aly is an employee of Novo Nordisk. Dalila Bajawi has received honorarium from Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Sanofi, Eli Lilly, Novartis, Bayer, Merck, Organon, Hikma, Tabuk and participated in trials sponsored by Novo Nordisk and Sanofi. Tarhan Cinar is an employee of Novo Nordisk. Dinesh Dhanwal has received honorarium from Novo Nordisk, Lilly, MSD, Boehringer Ingelheim, Hikma, AstraZeneca and participated in trials sponsored by Novo Nordisk and Lilly, Abdul Jabbar has received honorarium from Novo Nordisk, Lilly, Merck, Boehringer Ingelheim, Abbott, Novartis and participated in trials sponsored by Novo Nordisk, Said Khader has received honorarium from Novo Nordisk, BI, Sanofi, Lilly, AstraZeneca and participated in trials sponsored by Novo Nordisk and Sanofi. Khaled Khudadah has received honorarium from Novo Nordisk. Talal Muzaffar has nothing to disclose. Mary Ngome is an employee of Novo Nordisk. Jalal Nafach has received honorarium Novo Nordisk, Sanofi, MSD, Boehringer Ingelheim, Pfizer, AstraZeneca, P&G and participated in trials sponsored by Novo Nordisk, Sanofi, AstraZeneca, received non-financial support from Novo Nordisk, Amna Shaghouli has received honorarium from Novo Nordisk, Eli Lilly and Boehringer Ingelheim.
: The study was conducted in accordance with the Declaration of Helsinki. Approval was obtained from local institutional review boards, ethics committees and regulatory authorities (if applicable). All patients provided informed written consent to participate in the study. The institutional review boards included Jeddah Central Ministry of Health Institutional Review Board, Al Mouwasat Institutional Review Board, Sulaiman Al Habib central Institutional Review Board, King Fahad Medical City (KFMC), Almoosa hopital Institutional Review Board, Gulf Medical University Institutional Review Board, National Medical Commission (NMC) local Institutional Review Board. Regulatory bodies included Ministry of Health (MOH), Saudi Food and Drug Authority (SFDA), Dubai Health Authority (DHA), Ministry of Health and Prevention of the United Arab Emirates (MOHAP). The study is registered with ClinicalTrials.gov (NCT05716724).
